Starbucks denies that its decision to stop selling Chicken, Maple Butter, and Egg Sandwich on June 26, a mere five days after it had been announced as a new permanent menu item, was due to FDA recall or salmonella or listeria contamination.
A Starbucks spokesperson said that the Chicken, Maple Butter, and Egg Sandwich was given a voluntary stop sell and discard order by the company because it didn't live up to the company's high standards for quality.
The quality issue that was identified by Starbucks was simply about taste or based on another issue and would not lead to food-borne illness and any reports linking the stop sale to illness are inaccurate.
The spokesperson added that Starbucks is devoted to providing high-quality products, and anytime a concern about a product or its quality is expressed, we always proceed with extreme caution.


Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
The American mass exodus to Canada amid Trump 2.0 has yet to materialize
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock
Britain has almost 1 million young people not in work or education – here’s what evidence shows can change that
AI is driving down the price of knowledge – universities have to rethink what they offer
Yes, government influences wages – but not just in the way you might think
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Thailand Inflation Remains Negative for 10th Straight Month in January
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



